“Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s63. https://doi.org/10.25251/skin.5.supp.63.